Readystate Asset Management LP Raises Stock Position in Lumexa Imaging Holdings, Inc. $LMRI

Readystate Asset Management LP boosted its stake in Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) by 60.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 224,755 shares of the company’s stock after purchasing an additional 84,755 shares during the period. Readystate Asset Management LP’s holdings in Lumexa Imaging were worth $1,933,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in LMRI. Assetmark Inc. bought a new position in shares of Lumexa Imaging during the 4th quarter valued at $36,000. Strs Ohio bought a new stake in shares of Lumexa Imaging in the first quarter worth $38,000. PNC Financial Services Group Inc. purchased a new stake in Lumexa Imaging during the first quarter valued at $63,000. State of Wyoming bought a new position in Lumexa Imaging in the first quarter valued at about $91,000. Finally, Barclays PLC purchased a new position in Lumexa Imaging in the fourth quarter worth about $133,000.

Lumexa Imaging Stock Performance

Shares of Lumexa Imaging stock opened at $10.97 on Wednesday. The company has a market cap of $1.05 billion and a PE ratio of -18.59. The company has a current ratio of 1.40, a quick ratio of 1.40 and a debt-to-equity ratio of 1.43. The business has a fifty day moving average of $9.95. Lumexa Imaging Holdings, Inc. has a one year low of $6.45 and a one year high of $19.45.

Insider Buying and Selling at Lumexa Imaging

In related news, Director Brett Brodnax acquired 35,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The stock was bought at an average cost of $7.25 per share, for a total transaction of $253,750.00. Following the purchase, the director owned 62,027 shares in the company, valued at $449,695.75. The trade was a 129.50% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.70% of the stock is currently owned by insiders.

Analyst Ratings Changes

LMRI has been the subject of a number of recent research reports. Weiss Ratings upgraded Lumexa Imaging from a “sell (e)” rating to a “sell (d)” rating in a research note on Thursday, June 25th. Wall Street Zen raised shares of Lumexa Imaging from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. Finally, Barclays cut their target price on shares of Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating for the company in a research report on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $16.00.

About Lumexa Imaging

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).